Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus HALOTESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus HALOTESTIN.
DEPO-TESTOSTERONE vs HALOTESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
50-400 mg IM every 2-4 weeks
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Category D/X
Category C
Androgen
Androgen